Dublin, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/z7wd4k/plasma) has announced the addition of the "Plasma Fractionation Market by Product, Application & by End-user - Global Forecast to 2019" report to their offering.
The global plasma fractionation market is estimated to be worth around $16,573.4 million in 2014 and grow at a CAGR of 8.9% during the forecast period of 2014 to 2019. This market is mainly driven by increasing aging population, growing number of hemophilic patients, increased diagnosis rate, and growing prophylactic treatment. Moreover, the increasing off-label use of albumin and immunoglobulin in various chronic diseases is also contributing to market growth. However, the high cost and serious adverse effects of plasma products and the emergence of recombinant products are inhibiting market growth to a certain extent.
The global plasma fractionation market is divided on the basis of product, application, and end user. Based on type of product, the market is mainly segmented into albumin, immunoglobulins, coagulation factor concentrates, and others. The immunoglobulin segment is further subsegmented into intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), and others.
Coagulation factor concentrates are subsegmented into factor VIII, factor IX, factor XIII, prothrombin coagulation concentrates, Von Willebrand factors, and fibrinogen concentrates. Various applications such as neurology, hematology, immunology, and critical care are analyzed in the report. By end users, the market is divided into the hospitals and clinics, clinical research laboratories, and academic institutes segments.
By region, this market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW), which are further analyzed at the country-level. The research report discusses the key market drivers and restraints of, and the opportunities in, the global plasma fractionation market and its submarkets.
In 2013, the immunoglobulin segment accounted for the largest share of the market. This can be attributed to the increasing aging population with neurological and autoimmune disorders, off-label use, and prophylactic therapy of IVIg. In addition, IVIg is being used in a wide range of conditions such as adult respiratory distress syndrome, fibrosis, connective tissue disease, encephalitis, heart failure, and Alzheimer's disease. Positive results in such application areas would increase the demand for IVIg in the future.
North America represented the largest regional market in 2013, followed by Europe, Asia-Pacific, and RoW. The Asia-Pacific region represents the fastest-growing market for the plasma fractionation market, primarily due to the increasing aging population, growth in the overall healthcare industry, increasing use of immunoglobulins, improved economy, rising number of hemophilic patients, growing use of albumin in China, and increasing awareness of technologically advanced products in these regions.
Major players in the global market are Baxter International, Inc. (U.S.), Grifols SA (Spain), CSL Ltd. (Australia), Octapharma AG (Switzerland), Kedrion (Italy), Bio Product Laboratory (U.K.), Sanquin (Netherlands), Laboratoire Fran�ais du Fractionnement et des Biotechnologies (France), and Biotest (Germany).
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Global Plasma Fractionation Market, By Product
8 Global Plasma Fractionation Market, By Application
9 Global Plasma Fractionation Market, By End User
10 Global Plasma Fractionation Market, By Geography
11 Competitive Landscape
12 Company Profiles
13 Appendix
Companies Mentioned:
- Baxter International, Inc.
- Biotest
- Chinese Biological Products, Inc.
- Csl, Ltd.
- Grifols International SA
- Kedrion
- Kedrion S.P.A.
- LFB SA
- Octapharma AG
- Shanghai Raas Blood Products Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/z7wd4k/plasma